Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04837859 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Study acronym: INDIE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 26, 2024 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Start date changed from estimate of Dec 2023 to May 24, 2024
    • Primary completion date: Dec 2025 to May 2026
    • Study completion date: Dec 2027 to May 2028
    • Site details revised
  2. Re-verified, no change to tracked fieldsv4
  3. Primary completion date: Dec 2024 to Dec 2025
    • Start date: Dec 2022 to Dec 2023
    • Study completion date: Dec 2026 to Dec 2027
    v3
  4. Primary completion date: Dec 2023 to Dec 2024
    • Start date: Sep 2021 to Dec 2022
    • Study completion date: Sep 2025 to Dec 2026
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.
Trial Details
NCT Number NCT04837859
Lead Sponsor University of Cologne
Conditions
(from sponsor)		 Classical Hodgkin Lymphoma
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov